Intensive Studies for Recertification: Compounded Sterile Preparations Pharmacy Module 2 (Cert #L259101)

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in compounded sterile preparations pharmacy.

Board certified pharmacists are eligible to receive up to 4.0 contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline.   

ASHP provides an opportunity for remediation. Participants who are unsuccessful with the first assessment attempt may take a second assessment. The second assessment is included at no additional cost.

ASHP is approved by BPS as a provider for the recertification of BCSCP.

<797>: Gaps and Barriers
ACPE #: 0204-0000-25-124-H07-P

• Prioritize the nationally reported gaps for compliance with USP <797>.
• State common barriers to compliance with USP <797>.
• Design a sustainable plan for personnel competence requalification. 

Crafting a Valuable Plan for Viable Sampling 
ACPE #: 0204-0000-25-136-H07-P

• Identify the essential viable air and surface sampling locations for sterile compounding pharmacies.
• Select effective sampling locations for environmental quality and mitigation of contamination risks.
• Discuss the value of reassessing viable sample locations on an annual basis. 

Demystifying Disinfectants Used in Sterile Compounding Areas
ACPE #: 0204-0000-25-139-H07-P

• Apply United States Environmental Protection Agency information when interpreting disinfectant registration and performance data
• Describe the limitations of using isopropyl alcohol as a disinfectant.
• Identify appropriate disinfectants based on EPA classifications and contact times.
• Implement best practices for cleaning and disinfecting sterile compounding areas, including surface assessments, effective residue removal, and use of sporicidal agents against hard-to-kill organisms. 

Compounded Sterile Preparation Use Times: From Compounding to Administration
ACPE #: 0204-0000-25-132-H07-P

• Define key terminology used to describe the different use times of compounded sterile preparations.
• Interpret chemical stability and sterility test results for beyond-use date determination.
• Apply the principles of USP <797> to appropriate beyond-use date determination for various compounded sterile preparations.

Full faculty bios 

Kevin N. Hansen, PharmD, MS, BCSCP
Senior Director, Pharmacy Compounding Services
Premier Inc.

Patricia C. Kienle, RPh, MPA, BCSCP, FASHP
Director, Accreditation and Medication Safety
Cardinal Health 

Abby Roth, BS, CMQ/OE
Founder, Microbiologist
Pure Microbiology 

George Smith, PharmD, BCPS, BCSCP
System Sterile Compounding Services Specialist
Prisma Health

Sue Dombrowski, MS, RPh

Angela Cassano, PharmD, BCPS
Kevin N. Hansen, PharmD, MS, BCSCP
Patricia C. Kienle, RPh, MPA, BCSCP, FASHP

Phillip Chung, PharmD, BCSCP
Mark Court, PharmD, BCSCP
Ellen DoolingMcGurk, BSPha, BCPS, BCSCP
Adair Edmunds, PharmD, BCSCP
Brandon Griffith, BCSCP
Blaine Groat, PharmD, MS, BCSCP
Allison Hoff, BS Pharm, BCSCP
Will Horton, PharmD, MS, BCSCP
Dennis Hunt, RPh, BCSCP
Kim Hunt, BSPharm, BCSCP
Suzanne Kluge, BSPharm, BCSCP, MBA
Amy Knebel, PharmD, BCSCP
Natalie Kuchik, PharmD, MS, BCSCP
Richard Martin, PharmD, BCSCP
Pamela Mathis, PharmD, BCSCP
Vicki McConnell, BS Pharm, Pharm D, BCSCP, CPh
Sindhu Nair, PharmD, BCOP, BCSCP
Edmond Nunes, PharmD, MS, RPh, BCSCP
Jocelyn Reynoso, PharmD, BCPS, BCGP, BCSCP
Nicole Saul, PharmD, BCSCP
Ileana Soto, PharmD, BCSPS
Lori Watts, RPh/BCSCP
Jessica Woods, PharmD, BCSCP
George Zafiri, PharmD, BCSCP

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company. 

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience. 

No one in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company.

Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:

• Complete the attestation statement
• Review all content
• Complete and pass the assessments
• Complete the evaluations 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.

These activities were developed by ASHP.